RE:RE:RE:RE:RE:RE:AGM filled w details plus potential minor sht-term catalysts
I hope that you can understand the essence of my question. Most investors do some form of research before buying a stock. But if you were researching Bioniche you would be very confused by the company's own communication. The trial results are self explanatory and very compelling but what the heck is the market size for the drug?The potential market is somewhere between less than 10,000 annually to 600,000 annually or is it 200,000 to 600,000 or maybe even less than 10,000 to 200,000. I have been looking at this for several months but the facts seem to be all over the map. No wonder the stock has dropped since July. It is hard to make an investment decision when there is not accurate information at least accurate public infiormation. If this was a US company this information would be demanded by shareholders especially with this share performance.I thought that they would have this by now if they were talking to partners for a marketing relationship but it seems even the company is confused. Maybe they will pass this along to the analysts who are providing the research reports. I don't have any concept of how you could produce a research report with numbers that vary so wildly.